Clamart, France, 07 March, 2024 – MicroPort® is pleased to announce the completion of enrollment in TARGET FIRST trial.
The TARGET FIRST trial is a randomized controlled study that enrolled 2,246 patients in 40 European centers including France, Netherlands, Spain, Italy, Austria and Portugal.
The purpose of the study is to determine whether short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor (P2Y12i) monotherapy is non-inferior to standard DAPT for patients with Acute Myocardial Infarction (AMI) who underwent complete revascularization with Firehawk™, an abluminal in-groove biodegradable polymer rapamycin eluting stent. The therapy tested in this study aims at reducing the risk of bleeding events, while maintaining an adequate protection versus recurrent ischemic events.
Professor Giuseppe Tarantini, Principal Investigator of the study from the University Hospital of Padova, Italy, emphasized, "Our novel hypothesis seeks to optimize outcomes for acute myocardial infarction (AMI) patients by employing an innovative pharmaco-invasive strategy utilizing advanced stent technology coupled with comprehensive revascularization, thereby potentially reducing the necessity for dual antiplatelet therapy. We eagerly await the trial's findings."
The completion of patients’ enrollment marks the end of a three-year enrollment period. The follow-up phase of these patients will last 12 months. TARGET FIRST trial results are expected in the first half of 2025.
About the TARGET-FIRST trial:
TARGET-FIRST (ClinicalTrials.gov: NCT04753749) is a prospective, open-label, multicentre, randomized controlled study driven by MicroPort CRM clinical team. The study compares short (one month) Dual Antiplatelet Therapy (DAPT), versus standard (12 months) DAPT in a population of patients with non-ST/ST-segment elevation myocardial infarction, completely revascularized at index or staged procedure (within 7 days), using Firehawk™, an abluminal in-groove biodegradable polymer rapamycin-eluting stent. Patients underwent a mandatory 30-40 days of DAPT with aspirin and P2Y12i, then randomized in a 1:1 ratio to either stop DAPT immediately and receive P2Y12i monotherapy or continue DAPT with the same regimen for up to 12 months. The study is evaluating the primary endpoint of non-inferiority of short antiplatelet therapy in completely revascularized patients for net adverse clinical and cerebral events. If the primary endpoint is met, the study will also assess the main secondary endpoint of superiority of short DAPT in terms of major or clinically relevant non-major bleeding.
About MicroPort®:
Founded in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) is a global medical devices company. MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular and surgical robotics among others. For over 25 years, MicroPort® has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can continue living better and longer lives. With therapeutic solutions that are available in more than 100 countries and over 20,000 hospitals around the world, today, every 5 seconds a patient around the world benefits from a MicroPort® life-changing solution.
About MicroPort® CRM:
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM) and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Drawing on its extensive expertise in CRM, MicroPort® CRM develops, manufactures, and markets cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems, and ECG diagnostic solutions for managing cardiac rhythm disorders and heart failure globally. MicroPort® CRM also distributes MicroPort® products in Interventional Cardiology and Electrophysiology in Europe.
For more information, please visit www.microport.com.